Navigation Links
Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Date:9/9/2009

THE WOODLANDS, Texas, Sept. 9 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Morgan Stanley Global Healthcare Unplugged Conference at the Grand Hyatt hotel in New York, New York on Tuesday, September 15, 2009 at 1:35 p.m. Eastern Time.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
2. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
3. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
4. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
5. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
6. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
7. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
8. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
9. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
10. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , Feb. 17, 2017  If only one ... had a mutation-conferring resistance to chemotherapy, thousands of ... research has focused on finding these mutations in ... from circulating tumor DNA in blood — to ... therapeutics. Unfortunately, however, detecting these genetic ...
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute announced ... Larry Schlesinger as the Institute,s new President and ... effective May 31, 2017. He is currently the Chair of ... the Center for Microbial Interface Biology at Ohio State University. ... the new President and CEO of Texas Biomed," said Dr. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent ... availability of a new report, Sensors for Robotics: Technologies, Markets ... ... ... IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine ...
Breaking Biology News(10 mins):